Skip to main content
OpenTrials
Completed

NCT Number: NCT04335344

Role of suPAR in Periodontitis and CVD

soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum suPAR levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Disturbance Mouth Diseases Periodontal Diseases Stomatognathic Diseases

Age range

40 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Messina

Messina, 98125, Italy

About this study

The aim of this study was to evaluate a possible association between both saliva and serum suPAR levels in patients with CP and with CVD and if the serum suPAR levels are mediated by serum CRP.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presence of at least 15 teeth
  • CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm;
  • Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
  • Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion criteria

  • Intake of contraceptives
  • Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
  • Status of pregnancy or lactation
  • Previous history of excessive drinking
  • Allergy to local anaesthetic
  • Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Treatment and study plan

Observation of suPAR plasma and salivary levels

Other

Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Primary outcomes

  1. Clinical attachment level

    Time frame: 1-year

    evaluation of changes in clinical attachment level

Sponsors and collaborators

Lead sponsor

University of Messina

Other

Collaborators

  • University of Catania

Registry information

Official study title

Evaluation of Plasma and Salivary suPAR in Periodontitis and CVD Patients

Important dates

Study start
2015
Primary completion
2018
Study completion
2020
First posted
Apr 6, 2020
Registry last updated
Apr 7, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.